Lenalidomide-Associated ITP

الملخص EN

Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia.

The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described.

However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications.

Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.